VivoSim Labs (NASDAQ:VIVS) Releases Earnings Results

VivoSim Labs (NASDAQ:VIVS) released its earnings results on Wednesday. The company reported ($0.25) earnings per share for the quarter, FiscalAI reports. VivoSim Labs had a negative net margin of 11,016.07% and a negative return on equity of 355.66%. The company had revenue of $0.02 million for the quarter.

VivoSim Labs Trading Down 0.3%

Shares of VIVS stock traded down $0.00 on Friday, reaching $0.33. 903,715 shares of the company’s stock were exchanged, compared to its average volume of 2,893,191. VivoSim Labs has a 52 week low of $0.31 and a 52 week high of $5.30. The stock has a market capitalization of $1.14 million, a PE ratio of -0.07 and a beta of 1.47. The company’s fifty day simple moving average is $0.78 and its 200 day simple moving average is $1.37.

Institutional Trading of VivoSim Labs

An institutional investor recently bought a new stake in VivoSim Labs stock. Two Sigma Investments LP bought a new position in shares of VivoSim Labs, Inc. (NASDAQ:VIVS) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 23,192 shares of the company’s stock, valued at approximately $68,000. Two Sigma Investments LP owned about 0.89% of VivoSim Labs at the end of the most recent quarter. 8.23% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Separately, Weiss Ratings lowered shares of VivoSim Labs from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, May 22nd. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, VivoSim Labs has a consensus rating of “Sell”.

VivoSim Labs Company Profile

VivoSim Labs, Inc (NASDAQ: VIVS) is a biotechnology company specializing in the development and commercialization of advanced 3D human tissue models for preclinical drug testing and disease modeling. The company’s proprietary organoid platforms and cell-based assays are designed to replicate human physiological environments, enabling more predictive evaluation of drug efficacy, safety, and toxicity before clinical trials. By integrating cutting-edge bioengineering and microfluidics technologies, VivoSim Labs seeks to bridge the gap between traditional cell culture methods and human clinical outcomes.

The company’s product portfolio includes 3D bioprinted tissues, organ-on-a-chip systems, and disease-specific models targeting key therapeutic areas such as oncology, cardiology, and hepatology.